Navigation Links
The only European researcher to win this year's Early Career Bayer Hemophilia Award is Portuguese
Date:7/13/2011

Vanessa Oliveira, researcher at the Instituto de Medicina Molecular in Portugal won a prestigious and competitive Early Career Bayer Hemophilia Award. Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics. Oliveira was the only European researcher to win this award in 2010, in a total of 5 worldwide. The Portuguese researcher will receive US$170.000 to develop her project during two years.

Vanessa Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics. The treatment of hemophilia is based in the administration of laboratory produced clotting factors that the patients cannot make due to a genetic defect. However, a significant proportion of patients with severe hemophilia develop immune responses against these therapeutic clotting factors, which limits the efficacy of the treatment.

Although there have been several attempts to impair this undesired immune response, none of them has revealed efficient. Vanessa will study the causes for the limited efficacy of previously attempted methods to suppress undesirable immune response in hemophilia treatment, while developing new strategies to induce the patient's immune tolerance towards therapeutic clotting factors. This is a basic research project that will be developed in an animal model (mouse).

If results are promising, the project will be further developed to clinical studies. If Vanessas basic research is successful, it may help to improve the efficacy of current treatments. The project will be fully developed in Portugal, at the IMM's Cellular Immunology Unit, led by researcher Luis Graca.

The IMM's Cellular Immunology Unit has been developing cutting edge research in the area of immune-mediated diseases, such as asthma, transplantation and autoimmunity. The Unit's research has already resulted in the formation of a star-up company to develop a novel therapy to prevent liver transplant rejection.


'/>"/>

Contact: Marta Agostinho
marta-elisa@fm.ul.pt
351-918-486-058
Instituto de Medicina Molecular
Source:Eurekalert

Related medicine news :

1. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
2. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
3. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
4. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
5. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
6. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
7. European hematologist receives award to conduct research in US
8. European collaboration seeks to create World Wide Web for robots
9. HCL Thames Medics says more locum doctors could help address European Working Time Directive shortage
10. Third European Novel Food Approval Received by Tahitian Noni International
11. European Urology: Editorial about REDUCE trial underlines value of dutasteride
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Room (ER) on Wednesday, August 16, to community partners. The newly renovated ER ... “Fast Track” area for minor emergencies, eight semi-private rooms to deliver patient results, ...
(Date:8/17/2017)... ... 17, 2017 , ... An August 2 article on NextShark discusses ... largely influenced by the growing popularity of “pretty boys” in both K-Pop and television ... of male appearance are changing not only in the Asian nation, where plastic surgery ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... care professionals, today announced that it has raised $1.675 M in seed funding ... Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s primary ...
(Date:8/17/2017)... ... August 17, 2017 , ... Momkus McCluskey Roberts LLC ... Parks is a member of the firm’s Commercial Litigation and Employment Law groups. , ... wealth of knowledge in matters of employment litigation, commercial litigation and business disputes. Her ...
(Date:8/17/2017)... ... 2017 , ... Finalists in the 2017 (second annual) ... awards recognize the world’s best employers and the human resources professionals, teams, achievements ... to work. , A diverse group of organizations and individuals around the world ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) today ... effective Aug. 7, 2017. ... interests and will serve as president emeritus during a planned, ... in multiple leadership roles since he joined Diplomat with the ... provided decisive, strategic leadership which continues to benefit our patients ...
Breaking Medicine Technology: